411 related articles for article (PubMed ID: 31787582)
21. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Caremel R; Loutochin O; Corcos J
Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
[TBL] [Abstract][Full Text] [Related]
22. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
[TBL] [Abstract][Full Text] [Related]
23. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
24. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
25. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
26. Mirabegron: Pediatric First Approval.
Keam SJ
Paediatr Drugs; 2021 Jul; 23(4):411-415. PubMed ID: 34056686
[TBL] [Abstract][Full Text] [Related]
27. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.
Krhut J; Wohlfahrt P; Pudich J; Kufová E; Borovička V; Bílková K; Sýkora R; Mokriš J; Cífková R; Zachoval R; Zvara P
Int Urol Nephrol; 2021 Jun; 53(6):1089-1095. PubMed ID: 33417146
[TBL] [Abstract][Full Text] [Related]
29. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N
Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636
[TBL] [Abstract][Full Text] [Related]
31. Mirabegron in the treatment of overactive bladder.
Leone Roberti Maggiore U; Cardozo L; Ferrero S; Sileo F; Cola A; Del Deo F; Torella M; Colacurci N; Candiani M; Salvatore S
Expert Opin Pharmacother; 2014 Apr; 15(6):873-87. PubMed ID: 24646053
[TBL] [Abstract][Full Text] [Related]
32. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
33. Mirabegron: a safety review.
Tyagi P; Tyagi V; Chancellor M
Expert Opin Drug Saf; 2011 Mar; 10(2):287-94. PubMed ID: 21142693
[TBL] [Abstract][Full Text] [Related]
34. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
35. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
36. Mirabegron for the treatment of overactive bladder.
Gras J
Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
[TBL] [Abstract][Full Text] [Related]
37. The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder.
Balachandran AA; Duckett JR
Eur J Obstet Gynecol Reprod Biol; 2015 Apr; 187():60-3. PubMed ID: 25756594
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
39. Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
Chapple CR; Nitti VW; Khullar V; Wyndaele JJ; Herschorn S; van Kerrebroeck P; Blauwet MB; Siddiqui E
World J Urol; 2014 Dec; 32(6):1565-72. PubMed ID: 24458878
[TBL] [Abstract][Full Text] [Related]
40. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]